Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2004

View Archived Issues

Novel nonpeptide bradykinin B1 receptor antagonist from Sanofi-Synthelabo

Pain management by inhibition of glutamate carboxypeptidase II

Enhanced lipid-lowering effects found with an ezetimibe/simvastatin combination

Kos to acquire Azmacort franchise

Microscience achieves positive results with oral vaccine for travellers' diarrhea

Phenoxodiol evaluated in combination therapy for late-stage renal carcinoma

Schering to file for Asoprisnil E.U. approval in Q4 2005

Promising Alzheimer's vaccine tested in primates

VEGF Trap enters clinical development program

Argenta Discovery and AstraZeneca enter new research agreement

Four new SOAR collaborations for KRX-101

New water soluble polymers with hypocholesterolemic activity developed at Taisho

Banyu presents MCH1 antagonists and their use as antiobesity agents

Sodium channel blockers and their use in neuropathic pain claimed by Japanese team

New p38 MAP kinase inhibitors under study at GSK

Schering-Plough and Pharmacopeia report new CXCR ligands and their use

Dual NOS inhibitors/sodium channel modulators designed at SCRAS

NitroMed patent covers novel nitrosated H+/K+-ATPase inhibitors

Pfizer researchers report new inhibitors of TRK and other kinases for cancer therapy

Targeting thrombosis with plasma carboxypeptidase B inhibitors

Novel poly(ADP-ribose) polymerase-1 inhibitor restores sensitivity to temozolomide

Sinovac and Chinese CDC commence human influenza vaccine development

Ostabolin-C enters clinical trials

Phase II trial studies PT-100 combination therapy for advanced NSCLC

Iressa approved in Switzerland

Patient, physician satisfaction with Levitra

SuperGen clarifies interim data from phase III study of Dacogen in MDS

Successful completion of phase Ib study for DSC-104 in asthma

Nippon Kayaku reports in vivo effects of NK-082411 on micturition

Volume-regulated anion channel inhibitor prevents ischemia-induced arrhythmia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...